A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging.

Prostate-specific membrane antigen (PSMA)-targeted PET agents have revolutionized the care of patients with prostate cancer, supplanting traditional methods of imaging prostate cancer, and improving the selection and delivery of therapies. This has led to a rapid expansion in both the number of PSMA PET scans performed and the imaging specialists required to interpret those scans. To aid those imagers and clinicians who are new to the interpretation of PSMA PET, this review provides an overview of the interpretation of PSMA PET/CT imaging and pearls for overcoming commonly encountered pitfalls. We discuss the physiologic distribution of the clinically available PSMA-targeted radiotracers, the commonly encountered patterns of prostate cancer spread, as well as the benign and malignant mimics of prostate cancer. Additionally, we review the standardized PSMA PET reporting systems and the role of PSMA in selecting appropriate patients for PSMA-targeted therapies.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Steven P. Rowe reports a relationship with Lantheus Medical Imaging Inc that includes: consulting or advisory, funding grants, and speaking and lecture fees. Martin G. Pomper reports a relationship with Lantheus Medical Imaging Inc that includes: funding grants. Ashley E. Ross reports a relationship with Lantheus Medical Imaging Inc that includes: consulting or advisory. Michael A. Gorin reports a relationship with Lantheus Medical Imaging Inc that includes: consulting or advisory, funding grants, and speaking and lecture fees. Martin G. Pomper has patent with royalties paid to Lantheus.
(Copyright © 2023. Published by Elsevier Inc.)